KOSDAQBiotech & Pharma145020

Hugel

₩198,600▲ 3.12%2026-11-18 close
Market Cap
₩2.4T
Turnover
₩13B
Volume
70K
Shares out.
12.2M
PER
16.6×
PBR
1.9×
EPS
₩11,613
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

U.S. Direct-Sales Shift Tests Hugel's Profit Recovery

Revenue and operating profit grew together from 2022 to 2025, but in the third quarter of 2026 operating profit fell sharply on U.S. distribution-transition costs and lower botulinum toxin sales. The next thing to track is whether U.S. direct-sales profitability recovers quarter by quarter.

  1. 1

    On disclosed figures, 2025 revenue was KRW 425.1 billion, and operating margin rose from 36.0% in 2022 to 47.2% in 2025.

  2. 2

    Third-quarter 2026 revenue was KRW 97.5 billion, down 7.9% year on year, and operating profit was KRW 18.1 billion, down 61.8%. Net profit attributable to controlling shareholders fell 90.9% to KRW 3.36 billion.

  3. 3

    The company launched direct sales of its botulinum toxin Letybo in the U.S. on July 8, 2026, and set targets of 10% U.S. market share by 2028 and 14% by 2030.

  4. 4

    Overseas sales of toxin, fillers and skin boosters reached KRW 162.1 billion in the first half of 2026, about 64% of revenue (announced August 6, 2026), and the company ranked second in China with a 22% share (announced November 4, 2026).

  5. 5

    Third-quarter 2026 botulinum toxin sales fell 21% to KRW 47.2 billion, while combined domestic sales of toxin, fillers and skin boosters rose 54% to KRW 27.4 billion. Product-level trends diverged.

02

Business structure

Hugel is a medical aesthetics company that sells botulinum toxin, fillers and skin boosters, and cosmetics.

According to the company's announcement on November 4, 2026, third-quarter 2026 sales by product were KRW 47.2 billion for botulinum toxin (down 21% year on year), KRW 30.9 billion for fillers and skin boosters (up 2%), and KRW 19.4 billion for cosmetics and other (up more than 25%).

In the same quarter, combined domestic sales of toxin, fillers and skin boosters rose 54% to KRW 27.4 billion, and sales in Europe and other regions rose 18% to KRW 17.8 billion. The main product is the botulinum toxin Letybo, sold in Korea as Botulax; it received U.S.

FDA approval in March 2024 and was launched in the U.S. in March 2025 through partner Veneb. For the first half of 2026, announced August 6, toxin sales were KRW 149.4 billion, up 46.6%, fillers and skin boosters reached KRW 66.1 billion, and cosmetics and other reached KRW 39 billion.

Overseas sales of toxin, fillers and skin boosters totaled KRW 162.1 billion in the same period, about 64% of revenue. Customers are clinics and med spas, and in the U.S. the company targeted about 80 strategic accounts first for direct sales.

The cosmetics unit is anchored by the clinical cosmetics brand Welaxe, which is expanding its U.S. presence. Competition is most intense in the Korean toxin market, while in the U.S. the domestic rival Nabota's maker maintains its partnership with Evolus, and in China Hugel holds a 22% share and ranks second.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩105.9B₩47.4B44.8%
2025Q4₩119.1B₩57.8B48.5%
2026Q1₩116.6B₩47.6B40.8%
2026Q2₩137.9B₩56B40.6%
2026Q3₩97.5B₩18.1B18.6%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩281.7B₩101.4B₩57.3B36.0%7.2%23.6%
2023₩319.7B₩117.8B₩93.1B36.8%12.5%19.2%
2024₩373B₩166.2B₩135.8B44.6%16.9%11.7%
2025₩425.1B₩200.9B₩140.9B47.2%14.8%9.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On disclosed annual figures, revenue rose from KRW 281.7 billion in 2022 to KRW 425.1 billion in 2025, and it has grown for three consecutive years from 2023 through 2025. Operating profit rose from KRW 101.4 billion in 2022 to KRW 200.9 billion in 2025, with 2025 operating profit up 20.8% from the prior year.

Operating margin moved from 36.0% in 2022 to 36.8% in 2023, 44.6% in 2024 and 47.2% in 2025. Net profit attributable to controlling shareholders rose from KRW 57.3 billion in 2022 to KRW 140.9 billion in 2025, but its 2025 growth of 3.7% was well below the 20.8% growth in operating profit.

Net profit including non-controlling interests was KRW 147 billion in 2025. At the end of 2025, total liabilities were KRW 96.7 billion and total equity was KRW 980.2 billion, and the debt ratio fell from 23.6% in 2022 to 9.9% in 2025. Operating cash flow rose from KRW 80.6 billion in 2022 to KRW 150.1 billion in 2025.

On a quarterly basis, revenue was KRW 105.9 billion and operating profit KRW 47.4 billion in the third quarter of 2025, then rose to KRW 119.1 billion and KRW 57.8 billion in the fourth quarter.

First-quarter 2026 revenue was KRW 116.6 billion with operating profit of KRW 47.6 billion, and second-quarter revenue recovered to KRW 137.9 billion with operating profit of KRW 56 billion.

Third-quarter 2026 revenue fell to KRW 97.5 billion and operating profit to KRW 18.1 billion, while net profit attributable to controlling shareholders was KRW 3.36 billion, down 90.9% year on year.

The company attributed the third-quarter decline to a temporary effect of shifting its U.S. distribution partnership to a contract sales organization (CSO) model. Second-quarter operating profit fell 1.1% year on year as costs for building U.S. direct sales and early marketing investment were recorded.

Net profit attributable to controlling shareholders over the last four quarters (fourth quarter of 2025 to third quarter of 2026) totaled KRW 124.5 billion.

05

Industry analysis

The Korean botulinum toxin market is contested by several companies, and Hugel said its domestic toxin sales rose about 8% to KRW 20.5 billion in the second quarter of 2026. Press coverage read that as the company keeping its market position amid intense domestic competition.

In the third quarter of 2026, combined domestic sales of toxin, fillers and skin boosters rose 54% to KRW 27.4 billion.

Abroad, the U.S. is described as the largest medical aesthetics market, accounting for more than 50% of the global market, and reports said the average selling price there runs three to five times higher than in Korea. Press reports also noted that the U.S. med spa industry is growing quickly.

In the U.S. competitive picture, analysts pointed to the domestic rival Nabota's maker keeping its partnership with Evolus, so share shifts there are being watched.

Hugel holds a 22% share in China, ranking second, and said its Brazil business posted a record quarterly result in the third quarter of 2026 after re-entering the market.

In the same medical aesthetics sector, PharmaResearch has been expanding its launches in Western Europe, starting with the United Kingdom in December 2025. Across the sector, how a company organizes its overseas sales channels is emerging as a variable that shapes profitability.

06

Outlook

At the J.P. Morgan Healthcare Conference in January 2026, the company set a target of KRW 900 billion in company-wide revenue by 2028, with more than 30% coming from the U.S. For Letybo, the target is 10% U.S. market share by 2028 and 14% by 2030.

The company made direct sales official on July 8, 2026 in Los Angeles, and plans to focus first on about 80 strategic accounts and to expand U.S. direct-sales staff to 100 to 120 people by 2028. The company also set a target of up to 40% operating margin for its U.S. subsidiary by 2030.

In July 2026 press coverage, Shinhan Investment researcher Kim Ji-young estimated that U.S. direct-sales costs would be fully reflected and that the quarterly trough would occur, while expecting profit growth to continue through 2026.

Hana Securities researcher Kim Da-hye had said second-quarter operating margin would be the lowest of the year. Third-quarter 2026 operating profit fell to KRW 18.1 billion, so whether the expected trough holds in actual quarterly results is the next thing to check.

The supply contract with U.S. distribution partner Veneb runs until July 2027, and the company said no decision has been made on arrangements after that. The company is also preparing the U.S. launch of the topical skin booster Opulux V.

07

Valuation

PER
16.6×
PBR
1.9×
ROE
12.6%
EPS
₩11,613
BPS
₩98,707
Dividend per share
₩0

Valuation should be read against earnings scale and net asset value. Third-quarter 2026 net profit attributable to controlling shareholders fell to KRW 3.36 billion, so multiples calculated on the last four quarters' total of KRW 124.5 billion now move sharply with quarterly results.

In periods when earnings fall over a short span, the same share price produces a very different multiple, which makes simple comparison with past trading bands difficult.

The price-to-book ratio is read against controlling shareholders' equity of KRW 950.3 billion within total equity of KRW 980.2 billion at the end of 2025, and the shares trade above book value. Dividend yield is very low, so expectations of earnings growth rather than cash returns carry more weight in the share price.

Even within the sector, companies differ in overseas revenue mix and direct-sales strategy, which limits simple multiple comparisons. As earnings recovery is confirmed alongside stabilization of the U.S. direct-sales setup, the basis for reading the current multiple may change.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Rising overseas revenue share

Overseas sales of toxin, fillers and skin boosters reached KRW 162.1 billion in the first half of 2026, about 64% of revenue, and North and South American sales more than doubled year on year.

Hugel ranks second in China with a 22% share, and Brazil posted a record quarterly result in the third quarter of 2026 after re-entry. A broader overseas base is reducing reliance on any single market.

U.S. direct-sales price structure

Press reports say the average selling price in the U.S. runs three to five times the Korean level, so capturing distribution margin through direct sales raises revenue per unit. The company has set a target of up to 40% operating margin for its U.S. subsidiary by 2030. As direct sales grow as a share of the business, room for margin improvement widens.

Domestic toxin and filler bundling

Combined domestic sales of toxin, fillers and skin boosters rose 54% year on year to KRW 27.4 billion in the third quarter of 2026, and the company said these products have grown every quarter since the third quarter of 2025. Domestic toxin sales also rose about 8% in the second quarter of 2026. The company attributes its ability to hold domestic share in part to bundling toxins with fillers.

09

Bear factors

Sharp third-quarter profit drop

Third-quarter 2026 operating profit fell 61.8% to KRW 18.1 billion, and net profit attributable to controlling shareholders fell 90.9% to KRW 3.36 billion. Botulinum toxin sales dropped 21% to KRW 47.2 billion in the same quarter, so the decline in the main product drove the earnings fall.

With the last four quarters totaling KRW 124.5 billion, a single quarter's drop now carries more weight in the overall trend.

U.S. transition costs and near-term margin pressure

The company said a temporary effect from shifting its U.S. distribution partnership to a CSO model was reflected in third-quarter results. Analysts said a short-term decline in operating margin from U.S. direct sales is unavoidable.

Second-quarter operating profit also fell 1.1% year on year as costs for building direct sales and marketing investment were recorded.

Contract uncertainty and rising competition

The supply contract with U.S. partner Veneb runs until July 2027, and the company has said no decision has been made on arrangements after that. Competition remains intense in Korea, and in the U.S. the rival Nabota's maker maintains its partnership with Evolus. Whether the share targets are met could depend on partner terms and the competitive landscape.

10

Risk factors

U.S. direct-sales execution risk

U.S. direct sales depend on hiring, securing strategic accounts and executing marketing together. The company plans to expand U.S. direct-sales staff to 100 to 120 people by 2028, and the pace of hiring and sales productivity will determine whether costs track revenue. If costs rise ahead of sales, operating margin could fall further.

Distribution contract and partner risk

The supply contract with partner Veneb runs until July 2027, and the company has not decided what happens after that. Depending on the results of the hybrid model, the company could move to full direct sales or renegotiate with its partner. Changes in contract terms or partner sales volumes could alter the direction of U.S. revenue.

Toxin concentration and overseas regulatory risk

Toxin sales of KRW 149.4 billion in the first half of 2026 exceeded half of total revenue of KRW 254.5 billion. Because earnings are concentrated in one main product, pricing pressure or regulatory changes in individual markets could feed directly into results.

With overseas sales at about 64% of revenue, country-level approvals and exchange rates are also factors to watch.

11

What to watch next

  1. Late March 2027

    Filing of the 2026 annual business report. It will show full-year operating margin and the cost and revenue structure of U.S. direct sales on a disclosed annual basis for the first time.

  2. May 15, 2027

    Deadline for filing the first-quarter 2027 quarterly report. It is the point to check whether operating margin recovers quarter by quarter after the direct-sales launch and whether the trend after the third-quarter 2026 low continues.

  3. July 2027

    Expiry of the supply contract with U.S. partner Veneb. Whether the company renews, expands direct sales or changes its distribution approach will depend on the results of the hybrid model.

  4. End of 2028 (target year)

    The year the company has set for its targets of KRW 900 billion in company-wide revenue, more than 30% of revenue from the U.S., 10% U.S. market share and 100 to 120 direct-sales staff.

12

Overall view

Hugel's revenue, operating profit and net profit attributable to controlling shareholders all grew from 2022 to 2025, and operating margin rose from 36.0% to 47.2%. The debt ratio fell to 9.9% at the end of 2025, so financial leverage is small.

On the other hand, third-quarter 2026 revenue fell to KRW 97.5 billion and operating profit fell 61.8% to KRW 18.1 billion. The company points to temporary costs from shifting its U.S. distribution model, alongside a 21% drop in botulinum toxin sales.

Overseas sales now make up about 64% of revenue, and results in China and Brazil have been reported as strong. U.S. direct sales are presented as a basis for profitability improvement because of higher selling prices, but the third-quarter 2026 results do not yet confirm this.

Valuation is sensitive to quarterly swings given the last four quarters' earnings base. The next checkpoints are the 2026 annual business report, the first-quarter 2027 quarterly report and the expiry of the U.S. partner contract in July 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. pharmnews.com
  2. businesspost.co.kr
  3. e-science.co.kr
  4. news.bizwatch.co.kr
  5. econovill.com
  6. m.news.nate.com
  7. fnnews.com
  8. m.news.nate.com
  9. news.bizwatch.co.kr
  10. mt.co.kr
  11. m.news.nate.com
  12. newsway.co.kr
  13. asiatoday.co.kr
  14. m.news.nate.com
  15. m.news.nate.com
  16. srtimes.kr
  17. m.news.nate.com
  18. news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis